FIELD: pharmaceutics.
SUBSTANCE: present invention relates to novel cationic lipid of formula A or its any pharmaceutically acceptable salt, which are used to generate lipid nanoparticles (LNP) for delivery of oligonucleotides, to composition of lipid nanoparticles (LNP) containing disclosed cationic lipid and to use of cationic lipid. In formula A values R1, R2, R3, R', Rʺ, n, L1 and L2 are such as specified in patent claim.
EFFECT: novel low-molecular cationic lipids for delivery of oligonucleotides are described.
10 cl, 14 dwg, 2 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | 2011 |
|
RU2624045C2 |
TRIALKYL CATIONIC LIPIDS AND METHODS FOR USING THEM | 2013 |
|
RU2718053C2 |
LIPID COMPOUND AND COMPOSITION BASED THEREON | 2021 |
|
RU2825571C1 |
LIPID PARTICLES CONTAINING NUCLEIC ACIDS AND RELATED METHODS | 2010 |
|
RU2573409C2 |
LIPID NANOPARTICLES FOR IN VIVO MEDICINAL PRODUCTS DELIVERY AND THEIR USE | 2020 |
|
RU2799045C1 |
COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | 2018 |
|
RU2798342C2 |
FUSOGENIC COMPOUNDS FOR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | 2018 |
|
RU2808990C2 |
PEGYLATED LIPOSOMES FOR IMMUNOUGEN-CODING RNA DELIVERY | 2012 |
|
RU2628705C2 |
RNA PARTICLES INCLUDING POLYSARCOZINE | 2019 |
|
RU2792644C2 |
STABILIZED F RSV PROTEINS AND THEIR USE | 2019 |
|
RU2795459C2 |
Authors
Dates
2017-04-25—Published
2011-09-20—Filed